drugset / Trial / NCT06258148
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-parallel, multicenter phase 3 clinical trial to evaluate the efficacy of TG103 injection 7.5mg and 15mg once a week monotherapy compared with placebo in subjects with type 2 diabetes with poor glycemic control after diet and exercise.
Timeline
- Start
- 2024-04-15
- Primary completion
- 2026-01-23
- Completion
- 2026-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TG103 | Protein / enzyme biologic | 7.5 mg | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 15 mg | Subcutaneous |